Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.73) by 24.66 percent. The company reported quarterly sales of $41.691 thousand which missed the analyst consensus estimate of $4.046 million by 98.97 percent. This is a 95.83 percent decrease over sales of $1.000 million the same period last year.